OncoMatch/Clinical Trials/NCT06566092
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Is NCT06566092 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LN-145/LN-144 for soft tissue sarcoma.
Treatment: LN-145/LN-144 — This study is planned to test the safety and tolerability of the TIL regimen. The study will also test how well TIL fights cancer. The study will enroll children, teenagers, and young adults with solid tumors that have returned or are not responding to treatment for whom no effective standard-of-care treatment options exist. Study details include: * The study will last up to 2 years after the TIL infusion (Day 0) for each person. * The treatment will last up to 10 days for each person. * Study visits will be every 2 weeks until Day 42, every 6 weeks until Month 6, and every 3 months until Year 2.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Melanoma
Rhabdomyosarcoma
Lab requirements
Blood counts
Acceptable hematologic parameters
Kidney function
Adequate organ function
Liver function
Adequate organ function
Cardiac function
Modified Ross criteria class 1 and an LVFS > 25% or an LVEF ≥ 50%
Acceptable hematologic parameters. Adequate organ function. Modified Ross criteria class 1 and an LVFS > 25% or an LVEF ≥ 50%. Adequate pulmonary function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Colorado · Aurora, Colorado
- Johns Hopkins All Children's Hospital · St. Petersburg, Florida
- Rutgers Cancer Institute · New Brunswick, New Jersey
- Roswell Park Cancer Institute · Buffalo, New York
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify